GSK’s Zejula offers lasting PFS benefit in Phase III ovarian cancer trial

GSK has reported long-term findings from the Phase III PRIMA (ENGOT-OV26/GOG-3012) clinical trial where Zejula (niraparib) offered a lasting and clinically meaningful progression-free survival (PFS) benefit in ovarian cancer patients.